Lipe & Dalton purchased a new position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 824 shares of the biopharmaceutical company’s stock, valued at approximately $338,000.
A number of other large investors also recently bought and sold shares of the business. Whittier Trust Co. increased its position in shares of Regeneron Pharmaceuticals by 195.7% in the fourth quarter. Whittier Trust Co. now owns 68 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 45 shares in the last quarter. Smithfield Trust Co. acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth $27,000. Rehmann Capital Advisory Group increased its position in shares of Regeneron Pharmaceuticals by 1,700.0% in the third quarter. Rehmann Capital Advisory Group now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 68 shares in the last quarter. AdvisorNet Financial Inc increased its position in shares of Regeneron Pharmaceuticals by 208.0% in the fourth quarter. AdvisorNet Financial Inc now owns 77 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 52 shares in the last quarter. Finally, Harel Insurance Investments & Financial Services Ltd. acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter worth $29,000. 67.61% of the stock is currently owned by institutional investors.
REGN stock traded down $2.70 during mid-day trading on Friday, hitting $312.56. 383,451 shares of the company were exchanged, compared to its average volume of 789,309. The firm has a market cap of $34.12 billion, a P/E ratio of 15.79, a P/E/G ratio of 1.46 and a beta of 1.08. The company has a debt-to-equity ratio of 0.08, a current ratio of 4.58 and a quick ratio of 3.78. Regeneron Pharmaceuticals Inc has a twelve month low of $291.69 and a twelve month high of $442.00.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $4.45 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $5.24 by ($0.79). The company had revenue of $1.71 billion for the quarter, compared to analyst estimates of $1.76 billion. Regeneron Pharmaceuticals had a return on equity of 26.95% and a net margin of 35.13%. Regeneron Pharmaceuticals’s revenue was up 13.3% on a year-over-year basis. During the same period in the prior year, the business earned $4.67 earnings per share. On average, sell-side analysts expect that Regeneron Pharmaceuticals Inc will post 18.37 EPS for the current year.
In other news, EVP Neil Stahl sold 9,853 shares of the firm’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $305.74, for a total value of $3,012,456.22. Following the transaction, the executive vice president now directly owns 47,450 shares in the company, valued at approximately $14,507,363. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Joseph L. Goldstein sold 1,000 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $305.93, for a total transaction of $305,930.00. Following the completion of the transaction, the director now owns 11,323 shares in the company, valued at $3,464,045.39. The disclosure for this sale can be found here. Over the last three months, insiders have sold 141,968 shares of company stock valued at $57,360,056. 11.84% of the stock is owned by company insiders.
REGN has been the subject of several recent research reports. BidaskClub lowered shares of Regeneron Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, April 16th. Cantor Fitzgerald reaffirmed a “hold” rating and set a $441.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, February 6th. Oppenheimer raised their price target on shares of Regeneron Pharmaceuticals from $440.00 to $480.00 and gave the company an “outperform” rating in a report on Thursday, February 7th. Piper Jaffray Companies raised their price target on shares of Regeneron Pharmaceuticals to $487.00 and gave the company an “overweight” rating in a report on Tuesday, February 26th. Finally, Jefferies Financial Group lowered their price target on shares of Regeneron Pharmaceuticals from $376.00 to $343.00 and set a “hold” rating for the company in a report on Wednesday, April 17th. Two analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $397.44.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Further Reading: Gross Domestic Product (GDP)
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.